MedTrace Logo

AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment

NCT06611423 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-24

No results posted yet for this study

Summary

The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)
  • Renal Impairment

Interventions

BIOLOGICAL

AZD3427

AZD3427 SC injection to be prepared using AZD3427 diluent

OTHER

AZD3427 Placebo

AZD3427 Placebo

DRUG

Dopamine

Dopamine Hydrochloride 50mg/5mL

OTHER

Radiolabelled ligand

Injection of radioligand for PET examinations

OTHER

Saline

Saline solution

Sponsors & Collaborators

Principal Investigators

  • Kaveh Azizi, MD · Clinical Trial Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2025-08-21
Completion
2025-08-21

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06611423 on ClinicalTrials.gov